Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART, Journal of Antimicrobial Chemotherapy, December 2015, Oxford University Press (OUP),
DOI: 10.1093/jac/dkv427.
You can read the full text:
Contributors
The following have contributed to this page
